Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents

Full Query

IC:C07K16/10

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2021/009697HIV BINDING AGENTS
WO 21.01.2021
Int.Class A61P 31/18
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
12Antivirals
14for RNA viruses
18for HIV
Appl.No PCT/IB2020/056668 Applicant LAUSANNE UNIVERSITY HOSPITAL Inventor PANTALEO, Giuseppe
This disclosure relates to LN02M binding agents with specificity for HIV and to methods for using the same to treat, prevent and / or ameliorate HIV infection and/or AIDS. In some embodiments, this disclosure provides a binding agent(s) comprising a variable region shown in Figs. 6A through 6E; amino acid sequence of any mutant of Figs. 7A through 7D and/or Figs. 8A through 8F, and any effective (e.g., HIV neutralization) combination thereof; any one or more of SEQ ID NOS. 3-92, 95-233, 248-482, or 491-699; and/or combinations thereof.
2.WO/2021/005232INTRANASAL ADMINISTRATION OF NEUTRALISING ANTIVIRAL ANTIBODIES
WO 14.01.2021
Int.Class C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
Appl.No PCT/EP2020/069637 Applicant UMC UTRECHT HOLDING B.V. Inventor MAZUR, Natalie Isabelle
The current invention pertains to an antibody-comprising formulation for intranasal administration. The antibody-comprising formulation is particularly suitable for use in the prophylaxis or treatment of a viral infection of the respiratory tract. The invention in particular pertains to a formulation comprising neutralising anti-RSV antibodies for use in the treatment of prophylaxis of an RSV infection.
3.WO/2021/007285ANTI-HIV VACCINE ANTIBODIES WITH REDUCED POLYREACTIVITY
WO 14.01.2021
Int.Class C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
Appl.No PCT/US2020/041138 Applicant CALIFORNIA INSTITUTE OF TECHNOLOGY Inventor SIEVERS, Stuart, A.
This disclosure provides novel broadly neutralizing anti-HIV antibodies and antigen-binding fragments thereof. The disclosed anti-HIV antibodies exhibited improved biophysical properties, e.g, reduced polyreactivity, prolonged half-life, while retaining broad and potent neutralization activity. The anti-HIV bNAb variants as disclosed constitute a novel therapeutic strategy for treating and/or preventing HIV infection.
4.20210002355COMPOSITIONS AND METHODS FOR INHIBITING PATHOGEN INFECTION
US 07.01.2021
Int.Class C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
Appl.No 16982682 Applicant The University of North Carolina at Chapel Hill Inventor Samuel Lai

The presently-disclosed subject matter relates to antibodies, compositions, and methods for inhibiting and treating virus infection in the respiratory tract and virus transmission through the respiratory tract. In particular, the presently-disclosed subject matter relates to inhibiting and treating virus infection in a subject using compositions and antibodies that trap viruses in mucus of the respiratory tract, thereby inhibiting transport of virus across or through mucus secretions.

5.20210002354METHODS AND COMPOSITION FOR NEUTRALIZATION OF INFLUENZA
US 07.01.2021
Int.Class C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
Appl.No 16977327 Applicant The University of Chicago Inventor Patrick Wilson

Provided herein are anti-neuraminidase agents useful for neutralization of influenza virus infection, and methods of use and manufacture thereof. In particular, compositions comprising anti-neuraminidase agents (e.g., antibodies) that are cross-reactive with multiple influenza strains are provided, as well as methods of treatment and prevention of influenza infection therewith.

6.20210002381DE NOVO BINDING DOMAIN CONTAINING POLYPEPTIDES AND USES THEREOF
US 07.01.2021
Int.Class C07K 16/28
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
Appl.No 16824809 Applicant SUBDOMAIN, LLC Inventor David William LAFLEUR

Provided herein are de novo binding domain containing polypeptides (DBDpp) that specifically bind a target of interest. Nucleic acids encoding the DBDpp, and vectors and host cells containing the nucleic acids are also provided. Libraries of DBDpp, methods of producing and screening such libraries and the DBDpp identified from such libraries and screens are also encompassed. Methods of making and using the DBDpp are additionally provided. Such uses include, without limitation, affinity purification, and diagnostic and therapeutic applications.

7.20200407428THERAPEUTIC ANTIBODIES TO MARBURG VIRUS
US 31.12.2020
Int.Class C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
Appl.No 16491672 Applicant The Government of the United States of America as Represented by the Secretary of the Army Inventor Philippe THULLIER

Provided here are immunoglobulins and compositions containing one or more of said immunoglobulins reactive to a strain of Marburg virus. The immunoglobulins and compositions comprising said immunoglobulins can be used prophylactically to prevent a Marburg virus infection or to treat a patient that has been exposed to a Marburg virus in order to reduce a symptom.

8.20200405844COMBINATION HPIV3/HMPV RNA VACCINES
US 31.12.2020
Int.Class A61K 39/155
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
155Paramyxoviridae, e.g. parainfluenza virus
Appl.No 16897734 Applicant ModernaTX, Inc. Inventor Giuseppe Ciaramella

The disclosure relates to respiratory virus ribonucleic acid (RNA) vaccines and combination vaccines, as well as methods of using the vaccines and compositions comprising the vaccines.

9.11202011355QOPTIMIZED GP41-BINDING MOLECULES AND USES THEREOF
SG 30.12.2020
Int.Class C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
Appl.No 11202011355Q Applicant MACROGENICS, INC. Inventor LAM, Chia-Ying, Kao
(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau 11111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111 (43) International Publication Date 21 November 2019 (21.11.2019) (10) International Publication Number WO 2019/222104 Al WIPO I PCT (51) International Patent Classification: C07K 16/10 (2006.01) C07K 16/28 (2006.01) (21) International Application Number: PCT/US2019/032030 (22) International Filing Date: 13 May 2019 (13.05.2019) English English SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, 1E, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 21(3)) with sequence listing part of description (Rule 5.2(a)) (25) Filing Language: (26) Publication Language: (30) Priority Data: 62/673,462 18 May 2018 (18.05.2018) US (71) Applicants: MACROGENICS, INC. [US/US]; 9704 Medical Center Drive, Rockville, MD 20850 (US). DUKE UNIVERSITY [US/US]; 2812 Erwin Road, Durham, NC 27705 (US). (72) Inventors: LAM, Chia-Ying, Kao; 6020 Hawkcreek Place, San Jose, CA 95123 (US). DIEDRICH, Gundo; 13409 Bonnie Dale Drive, NorthPotomac, MD 20878 (US). NORDSTROM, Jeffrey, Lee; 18813 Rolling Acres Way, Olney, MD 20832 (US). LIU, Liqin; 23317 Ladrillo Street, Woodland Hills, CA 91367 (US). JOHNSON, Leslie, S.; c/o MacroGenics, Inc., 9704 Medical Center Drive, Rock- jville, MD 20850 (US). KOENIG, Scott; 10901 Ralston Road, Rockville, MD 20850 (US). HAYNES, Barton, F.; c/o Duke University, 2812 Erwin Road, Durham, NC 27705 (US). FERRARI, Guido; C/o Duke University, 2812 Er- win Road, Durham, NC 27705 (US). (74) Agent: AUERBACH, Jeffrey, I.; AuerbachSchrot LLC, 2200 Research Blvd., Suite 560, Rockville, MD 20850 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, Nre O CNI CNI CNI O CNI C (54) Title: OPTIMIZED GP41-BINDING MOLECULES AND USES THEREOF (57) Abstract: The present invention is directed to optimized HIV-1 gp41-Binding Molecules having reduced immunogenicity. More specifically, the invention relates to optimized gp41-Binding Molecules that comprise a gp41-binding Variable Light Chain (VL) Do- main and/or a gp41-binding Variable Heavy Chain (VH) Domain that has/have been optimized to reduce the immunogenicity of such Domain(s) upon administration to a recipient subject. The invention particularly pertains to gp41-Binding Molecules that are multispe- cific gp41-Binding Molecules (including bispecific diabodies (including DART® diabodies), BiTE®s, bispecific antibodies, trivalent binding molecules (including TRIDENTTM molecules), etc.) that comprise: (i) such optimized gp41-binding Variable Domain(s) and (ii) a domain capable of binding to an epitope of a molecule present on the surface of an effector cell. The invention is also directed to pharmaceutical compositions that comprise any of such gp41-Binding Molecules, and to methods involving the use of any of such gp41-Binding Molecules in the treatment of HIV-1 infection.
10.20200399349ANTIBODY AGAINST CHIKUNGUNYA VIRUS OR ANTIGEN-BINDING FRAGMENT OF THE ANTIBODY, AND USE OF THE SAME
US 24.12.2020
Int.Class C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
Appl.No 16968470 Applicant OSAKA UNIVERSITY Inventor Tatsuo SHIODA

The present invention provides a new antibody against ECSA type Chikungunya virus, WA type Chikungunya virus, and Asian type Chikungunya virus or an antigen-binding fragment of the antibody. The antibody against Chikungunya virus or the antigen-binding fragment of the antibody of the present invention includes a heavy chain variable region or a heavy chain (1), (2), or (3) and a light chain variable region or a light chain (4).